Atherosclerosis Therapeutics Market Size, Share and Growth Outlook, 2026

Atherosclerosis Therapeutics Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Atherosclerosis Therapeutics Market size is forecast to increase from $25.7 Billion in 2026 to $34.37 Billion in 2034 at a CAGR of 3.7% between 2026 and 2034.

The Atherosclerosis Therapeutics market report provides detailed analysis and outlook of Atherosclerosis Therapeutics segments including By Treatment Modality (Pharmacological Therapeutics / Medications, Interventional & Surgical Therapeutics), By Product Molecule Type (Small Molecules, Biologics / Large Molecules ), By Surgical Procedure (Angioplasty & Stenting, Coronary Artery Bypass Grafting, Atherectomy Procedures), By Distribution Channel (Hospital Pharmacies & Direct Tenders, Retail Pharmacies & Community Drugstores, Online & Mail-Order Pharmacies) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Atherosclerosis Therapeutics Industry Overview

Novel Cardiovascular Pathways Are Expanding the Atherosclerosis Treatment Landscape

The atherosclerosis therapeutics industry is evolving beyond traditional lipid-lowering and antithrombotic approaches as researchers increasingly target upstream biological mechanisms responsible for vascular injury and plaque progression. Atherosclerotic cardiovascular disease (ASCVD) remains closely associated with hypertension, chronic vascular inflammation, endothelial dysfunction, and hormonal pathways that contribute to arterial wall stress. As a result, pharmaceutical developers are investing in therapies capable of addressing the underlying drivers of cardiovascular disease rather than focusing solely on cholesterol management. This shift is creating opportunities for innovative therapeutic classes that support comprehensive cardiovascular risk reduction and long-term vascular protection.

Aldosterone Synthase Inhibition Emerges as a New Therapeutic Strategy

A major advancement within the industry is the approval of AstraZeneca’s Baxfendy® (baxdrostat), the first aldosterone synthase inhibitor approved for adults with uncontrolled hypertension. By selectively reducing aldosterone production, baxdrostat targets a key hormonal pathway responsible for fluid retention, elevated blood pressure, vascular remodeling, and chronic arterial stress. The approval highlights growing recognition of aldosterone as an important contributor to atherosclerosis progression and cardiovascular risk. Supporting this regulatory milestone, pivotal Phase III BaxHTN trial data published in the New England Journal of Medicine demonstrated highly significant dose-dependent reductions in seated systolic blood pressure across treatment-resistant patient populations. These findings validate aldosterone synthase inhibition as a novel therapeutic pathway with potential implications for reducing chronic vascular inflammation and slowing the development of atherosclerotic cardiovascular disease.

Regulatory Oversight Strengthening Evidence-Based Cardiovascular Care

Regulatory agencies are also increasing scrutiny of products making unsupported cardiovascular health claims. The FDA's compliance action against Meta Labs Pharmaceuticals underscores the industry's emphasis on evidence-based therapeutic interventions. Following a facility inspection, regulators ordered the cessation of unapproved marketing claims associated with dietary supplements containing ingredients such as nattokinase that were promoted as safer-than-aspirin alternatives for reducing blood coagulation, lowering atherosclerosis risk, and preventing coronary heart disease. This action highlights the growing importance of scientifically validated therapies and reinforces the distinction between approved pharmaceutical treatments and unsubstantiated supplement claims. As cardiovascular disease management becomes increasingly sophisticated, healthcare providers are prioritizing clinically proven therapies supported by robust regulatory review and large-scale clinical evidence.

Atherosclerosis Therapeutics Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Atherosclerosis Therapeutics market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Novartis AG, Amgen Inc., AstraZeneca plc, Pfizer Inc., Sanofi S.A., Esperion Therapeutics, Inc., NewAmsterdam Pharma, Silence Therapeutics, Bayer AG, AbbVie Inc.. The Atherosclerosis Therapeutics market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Atherosclerosis Therapeutics industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Atherosclerosis Therapeutics Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Atherosclerosis Therapeutics companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Atherosclerosis Therapeutics markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Atherosclerosis Therapeutics Market Competitive Benchmarking and Company Analysis

Leading companies in Atherosclerosis Therapeutics industry include- Novartis AG, Amgen Inc., AstraZeneca plc, Pfizer Inc., Sanofi S.A., Esperion Therapeutics, Inc., NewAmsterdam Pharma, Silence Therapeutics, Bayer AG, AbbVie Inc.. The Atherosclerosis Therapeutics market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Atherosclerosis Therapeutics Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Atherosclerosis Therapeutics market remains one of the strongest-performing segments in the country.
The US Atherosclerosis Therapeutics Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Atherosclerosis Therapeutics market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Atherosclerosis Therapeutics industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Atherosclerosis Therapeutics markets

Canada's strong Atherosclerosis Therapeutics sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Atherosclerosis Therapeutics market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Atherosclerosis Therapeutics Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Atherosclerosis Therapeutics market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Atherosclerosis Therapeutics population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Atherosclerosis Therapeutics industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Atherosclerosis Therapeutics market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Atherosclerosis Therapeutics sales through 2034

France Atherosclerosis Therapeutics companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Atherosclerosis Therapeutics Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Atherosclerosis Therapeutics distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Atherosclerosis Therapeutics Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Atherosclerosis Therapeutics market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Atherosclerosis Therapeutics industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Atherosclerosis Therapeutics industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Atherosclerosis Therapeutics Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Atherosclerosis Therapeutics market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Atherosclerosis Therapeutics market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Atherosclerosis Therapeutics Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Atherosclerosis Therapeutics Market Segmentation

By Treatment Modality
Pharmacological Therapeutics / Medications
Interventional & Surgical Therapeutics
By Product Molecule Type
Small Molecules
Biologics / Large Molecules
By Surgical Procedure
Angioplasty & Stenting
Coronary Artery Bypass Grafting
Atherectomy Procedures
By Distribution Channel
Hospital Pharmacies & Direct Tenders
Retail Pharmacies & Community Drugstores
Online & Mail-Order Pharmacies

Top Companies in Atherosclerosis Therapeutics Industry

Novartis AG
Amgen Inc.
AstraZeneca plc
Pfizer Inc.
Sanofi S.A.
Esperion Therapeutics, Inc.
NewAmsterdam Pharma
Silence Therapeutics
Bayer AG
AbbVie Inc.

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025